𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Four years' experience with the treatment of all-trans retinoic acid in acute promyelocytic leukemia

✍ Scribed by Dr. Xingzhong Wu; Xuewen Wang; Xiaoping Qien; Hainin Liu; Jianshang Ying; Zhicheng Yang; Haiqien Yao

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
640 KB
Volume
43
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

ALL-TRANS RETINOIC ACID (ATRA) IN THE TR
ALL-TRANS RETINOIC ACID (ATRA) IN THE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
✍ C. S. CHIM; Y. L. KWONG; R. LIANG; Y. C. CHU; C. H. CHAN; L. C. CHAN; K. F. WONG πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 498 KB πŸ‘ 2 views

Acute promyelocytic leukemia is characterized by the reciprocal translocation of chromosomes 15 and 17. All-trans retinoic acid (ATRA) efficiently induces differentiation of the abnormal promyelocytes. In this study, we had used ATRA as the primary induction therapy for 17 newly diagnosed patients,

Pharmacology of all-trans-retinoic acid
Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia
✍ Lanvers, Claudia ;Reinhardt, Dirk ;DΓΌbbers, Angelika ;Wagner-Bohn, Alexandra ;Cr πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 158 KB πŸ‘ 1 views

## Abstract ## Background Due to severe side effects in virtually all children treated with a standard dose of 45 mg/m^2^/day all‐__trans__‐retinoic acid (ATRA) for acute promyelocytic leukemia (APL) the AML‐BFM study group reduced the dosage to 25 mg/m^2^/day. For the lack of data on the use of A

Treatment of acute promyelocytic leukemi
Treatment of acute promyelocytic leukemia with all-trans retinoic acid during the third trimester of pregnancy
✍ Reiko Watanabe; Shinichiro Okamoto; Takanori Moriki; Masahiro Kizaki; Yoko Kawai πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 240 KB πŸ‘ 2 views

## Response to "Treatment of Childhood Chronic ITP" Prompted by recent correspondence in the Journal (July 1994), may I contribute the experience from this center in the use of megadose prednisone for chronic immune thrombocytopenic purpura (ITP) in children? A cohort of 4 children received this